Revelation Biosciences
REVB
13 hedge funds and large institutions have $52M invested in Revelation Biosciences in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
8% more funds holding
Funds holding: 12 → 13 (+1)
2% more capital invested
Capital invested by funds: $50.7M → $52M (+$1.26M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$4.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$4.04M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$49K |
REVB Hedge Fund Activity: Q2 2021 in Review
13 institutional investors reported a position in Revelation Biosciences (REVB) for Q2 2021, worth a combined $52M — up 2.5% from $50.7M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new REVB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Weiss Asset Management, opening a new position worth an estimated $4.04M. The largest seller was Boothbay Fund Management, cutting an estimated $4.04M.
- 13 institutional investors held Revelation Biosciences (REVB) as of Q2 2021, up from 12 in Q1 2021.
- Funds reported $52M of Revelation Biosciences stock for Q2 2021, up 2.5% quarter-over-quarter.
- 1 fund opened new Revelation Biosciences positions in Q2 2021 and 0 closed out, a net change of +1 holder.
- The largest Revelation Biosciences buyer in Q2 2021 was Weiss Asset Management, an estimated $4.04M added.
- The largest Revelation Biosciences seller in Q2 2021 was Boothbay Fund Management, an estimated $4.04M sold.
Based on aggregated 13F filings for Q2 2021.